MX2017006702A - Conjugados de cisteamina y ácidos grasos y su uso como activadores de la autofagia. - Google Patents

Conjugados de cisteamina y ácidos grasos y su uso como activadores de la autofagia.

Info

Publication number
MX2017006702A
MX2017006702A MX2017006702A MX2017006702A MX2017006702A MX 2017006702 A MX2017006702 A MX 2017006702A MX 2017006702 A MX2017006702 A MX 2017006702A MX 2017006702 A MX2017006702 A MX 2017006702A MX 2017006702 A MX2017006702 A MX 2017006702A
Authority
MX
Mexico
Prior art keywords
disease
fatty acid
autophagy
mercaptoethyl
idiopathic pulmonary
Prior art date
Application number
MX2017006702A
Other languages
English (en)
Inventor
R Jirousek Michael
B Vu Chi
Original Assignee
Catabasis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catabasis Pharmaceuticals Inc filed Critical Catabasis Pharmaceuticals Inc
Publication of MX2017006702A publication Critical patent/MX2017006702A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a (i) conjugados de cisteamina y ácidos grasos sustituidos con heteroarilo de 6 miembros composiciones de estos, métodos para tratar enfermedades que implican la desregulación de la autofagia, tales como fibrosis quística, fibrosis pulmonar idiopática (IPF), una enfermedad neurodegenerativa, enfermedad inflamatoria, enfermedad del hígado, enfermedad muscular, infección y enfermedad inmunitaria con este compuesto, o (ii) un método para tratar la fibrosis pulmonar idiopática, enfermedades mitocondriales, síndrome de Leigh, diabetes Mellitus y sordera (DAD), neuropatía óptica hereditaria de Leber, ptosis y neuropatía, ataxia y retinitis pigmentosa (NARP), síndrome de encefalopatía mioneurogastrointesti nal (MNGIE), epilepsia mioclónica asociada a fibras rojas rasgadas (MERRF), o miopatía, encefalopatía, acidosis láctica y episodios semejantes a apoplejías mitocondriales (MELAS), que comprende administrar a un paciente el conjugado de cisteamina y ácidos grasos, (4Z, 7Z. 10Z, 13Z, 16Z, 19Z)-N-(2-mercaptoetil) docosa-4,7,10,13,16,19-hexaenamida o (5Z,8Z, 11Z, 14Z, 17Z)-N-(2-mercaptoetil) icosa-5, 8,11,14, 17-pentaenamida.
MX2017006702A 2014-11-26 2015-11-25 Conjugados de cisteamina y ácidos grasos y su uso como activadores de la autofagia. MX2017006702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462084754P 2014-11-26 2014-11-26
PCT/US2015/062620 WO2016086103A1 (en) 2014-11-26 2015-11-25 Fatty acid cysteamine conjugates and their use as activators of autophagy

Publications (1)

Publication Number Publication Date
MX2017006702A true MX2017006702A (es) 2018-01-11

Family

ID=56075027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006702A MX2017006702A (es) 2014-11-26 2015-11-25 Conjugados de cisteamina y ácidos grasos y su uso como activadores de la autofagia.

Country Status (14)

Country Link
US (2) US10251845B2 (es)
EP (1) EP3223818A4 (es)
JP (1) JP2017535579A (es)
KR (1) KR20170087926A (es)
CN (1) CN107205994A (es)
AU (1) AU2015353492A1 (es)
BR (1) BR112017010872A2 (es)
CA (1) CA2968402A1 (es)
HK (1) HK1243322A1 (es)
IL (2) IL252456A0 (es)
MA (1) MA41031A (es)
MX (1) MX2017006702A (es)
RU (1) RU2017121906A (es)
WO (1) WO2016086103A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
ES2624554T3 (es) 2005-12-28 2017-07-14 Vertex Pharmaceuticals Incorporated Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
SI2674428T1 (sl) 2006-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Modulatorji transporterjev atp-vezavne kasete
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
DK2639224T3 (en) 2007-12-07 2016-10-17 Vertex Pharma A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
NZ702159A (en) 2007-12-07 2016-03-31 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
EP2408750B1 (en) 2009-03-20 2015-08-26 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP3150198B1 (en) 2010-04-07 2021-09-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
EP3045452A1 (en) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Process of producing cycloalkylcarboxamido-indole compounds
NZ629199A (en) 2012-02-27 2017-01-27 Vertex Pharma Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
KR102280372B1 (ko) 2013-11-12 2021-07-22 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
HUE062736T2 (hu) 2014-04-15 2023-12-28 Vertex Pharma Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2018144981A1 (en) * 2017-02-06 2018-08-09 StemBios Technologies, Inc. Use of somatic stem cells for increasing autophagy
US11566044B2 (en) 2017-07-26 2023-01-31 The University Of Queensland Disulfide bond containing compounds and uses thereof
AU2019370363A1 (en) * 2018-10-30 2021-05-13 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis
GB2581362A (en) 2019-02-14 2020-08-19 Univ Of Sunderland Chemical synthesis
EP4034557A4 (en) * 2019-09-25 2023-01-18 Frontier Medicines Corporation TARGETED AUTOPHAGIC CONJUGATES AND METHODS
US20230099696A1 (en) * 2020-03-11 2023-03-30 Purdue Research Foundation Nano-composite microparticles of polymyxin
WO2022109198A1 (en) * 2020-11-19 2022-05-27 Birch Therapeutics, Inc. Cystamine formulations and uses thereof
CN115724786B (zh) * 2021-09-01 2024-01-30 四川大学 酰胺烷二硫邻苯二甲酰亚胺类化合物、其制备方法和用途
CN115806514B (zh) * 2022-12-06 2024-06-04 航天材料及工艺研究所 一种基于动态二硫键的无溶剂型自修复聚氨酯及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
MX2011000273A (es) 2008-07-08 2011-05-23 Catabasis Pharmaceuticals Inc Salicilatos acetilados con acidos grasos y sus usos.
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
SG10201500431SA (en) 2009-09-01 2015-03-30 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
WO2011044136A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid acipimox derivatives and their uses
US20110082202A1 (en) 2009-10-05 2011-04-07 Milne Jill C Fatty acid acifran derivatives and their uses
US20110082210A1 (en) 2009-10-05 2011-04-07 Milne Jill C Fatty acid fibrate derivatives and their uses
WO2011044140A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
WO2011044138A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Lipoic acid acylated salicylate derivatives and their uses
MX337605B (es) 2010-01-08 2016-03-10 Catabasis Pharmaceuticals Inc Derivados de fumarato de acido graso y sus usos.
US20110212958A1 (en) 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Fatty acid raloxifene derivatives and their uses
WO2011106688A1 (en) 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
US20110213028A1 (en) 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Fatty acid mycophenolate derivatives and their uses
WO2011109681A1 (en) 2010-03-05 2011-09-09 Catabasis Pharmaceuticals, Inc. Fatty acid cox inhibitor derivatives and their uses
WO2011116312A1 (en) 2010-03-19 2011-09-22 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2012161798A1 (en) 2011-02-25 2012-11-29 Catabasis Pharmaceuticals, Inc. Fatty acid gamma aminobutyric acid (gaba) conjugates and their uses
EP2685969A4 (en) 2011-03-18 2014-08-06 Catabasis Pharmaceuticals Inc USE OF INTRACELLULAR ENZYMES TO RELEASE BIOACTIVE PRODUCTS RELATED TO COVALENCE
US20120252810A1 (en) 2011-04-04 2012-10-04 Catabasis Pharmaceuticals, Inc. Fatty acid non-flushing niacin derivatives and their uses
US9150504B2 (en) 2011-04-29 2015-10-06 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses
WO2012154564A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid phenolic derivatives and their uses
US9029548B2 (en) 2011-05-06 2015-05-12 Catabasis Pharmaceuticals, Inc. Fatty acid lenalidomide derivatives and their uses
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
WO2014045293A1 (en) 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
US20130059801A1 (en) 2011-08-31 2013-03-07 Catabasis Pharmaceuticals, Inc. Fatty acid amides, compositions and methods of use
CA2847418A1 (en) 2011-08-31 2013-03-07 Jill C. Milne Fatty acid amides useful in the treatment of inflammatory disorders
US20130244966A1 (en) 2011-12-12 2013-09-19 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
EP2844257A4 (en) 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
EP3210972A1 (en) 2012-05-25 2017-08-30 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA2896776A1 (en) 2013-01-07 2014-07-10 Jean E. Bemis Use of fatty acid niacin conjugates for treating diseases
US20140288025A1 (en) 2013-03-13 2014-09-25 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
WO2014204856A1 (en) 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Fatty acid anticancer derivatives and their uses
JP2016537353A (ja) 2013-11-15 2016-12-01 カタバシス ファーマシューティカルズ，インコーポレイテッド 脂肪酸ナイアシン複合体
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016086136A1 (en) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
US20170342046A1 (en) 2016-05-24 2017-11-30 Catabasis Pharmaceuticals, Inc. Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders

Also Published As

Publication number Publication date
EP3223818A4 (en) 2018-04-25
BR112017010872A2 (pt) 2018-01-09
US10251845B2 (en) 2019-04-09
HK1243322A1 (zh) 2018-07-13
EP3223818A1 (en) 2017-10-04
AU2015353492A1 (en) 2017-06-08
MA41031A (fr) 2017-10-03
CA2968402A1 (en) 2016-06-02
US20170258741A1 (en) 2017-09-14
US20200038342A1 (en) 2020-02-06
IL252456A0 (en) 2017-07-31
WO2016086103A1 (en) 2016-06-02
CN107205994A (zh) 2017-09-26
RU2017121906A (ru) 2018-12-26
JP2017535579A (ja) 2017-11-30
IL275578A (en) 2020-08-31
RU2017121906A3 (es) 2019-06-03
KR20170087926A (ko) 2017-07-31

Similar Documents

Publication Publication Date Title
MX2017006702A (es) Conjugados de cisteamina y ácidos grasos y su uso como activadores de la autofagia.
MY165906A (en) Phenothiazine diaminium salts and their use
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
CY1123137T1 (el) Ιμιδαζο[1.2α]πυριδινες για αντιμετωπιση ή προληψη υπερουριχαιμιας ή ουρικης αρθριτιδας
AR099134A1 (es) Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
JP2016130266A5 (es)
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
AR111570A1 (es) Composición farmacéutica que comprende selexipag
PE20000556A1 (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla
PH12017501427A1 (en) Benzoxaborole compounds and uses thereof
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
MX2015011074A (es) Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
MA54939A (fr) Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2
MX2019007626A (es) Producto para el cuidado bucal y metodos de uso y fabricacion de este.
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
WO2018232005A3 (en) Antimicrobial compounds and nanostructures
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
CU20190042A7 (es) Compuestos derivados de naftiridinona

Legal Events

Date Code Title Description
FG Grant or registration